Mark McKenna, Mirador Therapeutics CEO
March 21, 2024 07:00 AM EDT
Financing
Startups

For­mer Prometheus ex­ecs raise $400M for pre­ci­sion im­munol­o­gy start­up: 'The band is back to­geth­er'

Ryan Cross

Senior Science Correspondent

Af­ter sell­ing his last com­pa­ny to Mer­ck for $10.8 bil­lion in June, Mark McKen­na couldn’t shake the feel­ing that he’d left the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times